[HTML][HTML] European Association of Urology guidelines on renal cell carcinoma: the 2022 update
B Ljungberg, L Albiges, Y Abu-Ghanem, J Bedke… - European urology, 2022 - Elsevier
Abstract Context The European Association of Urology (EAU) Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
M Rosellini, A Marchetti, V Mollica, A Rizzo… - Nature Reviews …, 2023 - nature.com
The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …
immunotherapy agents by regulatory agencies. However, objective and durable responses …
Management of metastatic clear cell renal cell carcinoma: ASCO guideline
WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
European association of urology guidelines on renal cell carcinoma: the 2019 update
B Ljungberg, L Albiges, Y Abu-Ghanem, K Bensalah… - European urology, 2019 - Elsevier
Abstract Context The European Association of Urology Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
[PDF][PDF] Treatment of renal cell carcinoma: current status and future directions
Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger… - Annals of …, 2019 - annalsofoncology.org
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women,
respectively, thus representing the 7th most common cancer in men, and the 10th most …
respectively, thus representing the 7th most common cancer in men, and the 10th most …
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir… - The lancet …, 2016 - thelancet.com
Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Background Treatment for renal cell carcinoma has been revolutionised by inhibitors of
VEGF receptor. Previous studies have suggested that treatment with a VEGF receptor …
VEGF receptor. Previous studies have suggested that treatment with a VEGF receptor …
First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis
Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …
Prognostic factors and prognostic models for renal cell carcinoma: a literature review
T Klatte, SH Rossi, GD Stewart - World journal of urology, 2018 - Springer
Purpose Following curative treatment for localised renal cell carcinoma (RCC), up to 30% of
patients develop tumour recurrence. Prognostic scores are essential to guide individualised …
patients develop tumour recurrence. Prognostic scores are essential to guide individualised …